Meunier Carlin & Curfman manages critical intellectual property matters for biotechnology companies, universities, and research institutions. Our attorneys and patent agents, including several with PhDs, have a broad spectrum of expertise in areas that include molecular biology, cellular biology, immunology, microbiology, molecular pathogenesis, and genetics.
With our understanding of both the technologies and the science that undergird biotechnology, we are able to provide complete and coordinated counsel to biotech developers, from the earliest stages of innovation to commercialization.
Our Biotech Clients: Companies, Universities, and Research Institutions
We represent clients in every stage of biotechnology development, including startup, growth-stage, and large multinational biotechnology companies. We help these companies navigate the risks and uncertainty of product development through the effective use of patent prosecution, patent opinions, and the management of patent portfolios.
Of course, academic research institutions play a crucial role in the development of biotechnology. We have extensive experience working with universities and research institutes to protect biotech innovation and develop patent portfolios that can be licensed or used to spin out startup ventures.
Our work in the biotech sector is wide-ranging, including medicine, agriculture, pharmaceuticals, and food and dietary supplements. Technologies we have handled include innovations in the fields of:
- Biomedical therapeutics and diagnostics
- Industrial processes
- Protein and genetic engineering
- Tissue engineering
Biotech IP Services
We guide biotech innovators through the patent prosecution process and assist with managing and protecting patent portfolios. We also assist clients in seeking patent protection in foreign jurisdictions.
Our team handles opinions on patentability, patent infringement, validity, and freedom to operate (or right to use) issues. We also advise clients on complex corporate, joint venture, and licensing matters. When necessary, we represent clients in litigation relating to biotechnology, including matters of infringement and unfair competition.